12 April 2018
MSD Animal Health Calls for Tilapia Science Award Submissions
Applications Due by August 3, 2018
MADISON, NJ, April 12, 2018 – MSD Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA, is proud to announce its sponsorship of the 2018 High Quality Tilapia Science Award in support of research in tilapia health, production and welfare. The company will award one recent graduate in veterinary or animal science with the opportunity to present their research to an impressive number of industry specialists at an upcoming MSD Animal Health High Quality Tilapia meeting to be held in October 2018 in São Paulo, Brazil.
“MSD Animal Health is proud to invest in the future of young researchers,” said Chris Beattie, Ph.D., Head of Aquaculture, MSD Animal Health. “With growing demand for safe, affordable protein, the tilapia industry is working hard to ensure the health and welfare of the stocks they are rearing. It is our hope to establish lasting relationships with recent graduates who are leading the way in important research and innovation that will benefit tilapia health, production, and welfare.”
To apply, candidates must submit a 300-word summary of their research project, resume and a brief letter describing why their work contributes to the improvement of the tilapia industry to this email address. Applications must be submitted by August 3, 2018.
Eligible graduates must have completed, at minimum, a Bachelor’s degree in the past 12 months and have completed research for an applied project in either veterinary or animal science with an emphasis on tilapia. Topics of interest include antibiotic reduction, welfare, precision medicine, innovations in aquaculture, infectious diseases, and parasite challenges and solutions.
The winner will be notified no later than September 7, 2018, and must be available to present their research at the 2018 High Quality Tilapia congress in São Paulo, Brazil, on October 1-5, 2018. The company will assume responsibility for travel expenses incurred.
About MSD Animal Health
For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. MSD Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA, is the global animal health business unit of MSD. Through its commitment to the Science of Healthier Animals™, MSD Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. MSD Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.msd-animal-health.com or connect with us on LinkedIn and Twitter.
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2017 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).